Ipamorelin & CJC-1295 Research Guide
A research reference covering the mechanisms, synergy, and laboratory applications of two of the most studied growth hormone-related peptides available in Canada.
Ipamorelin and CJC-1295 are two distinct growth hormone-related research peptides that have been widely studied in preclinical settings. Each operates through a separate receptor pathway, and when combined, they produce synergistic effects on growth hormone pulse amplitude that exceed what either compound achieves independently.
This guide covers the mechanisms of action, downstream research applications, and the key differences between CJC-1295 DAC and No DAC formulations — for laboratory and research reference purposes only.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) — the endogenous peptide responsible for stimulating GH release from the anterior pituitary. In research models, CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, triggering cAMP/PKA signaling cascades that increase GH gene expression and promote calcium-mediated hormone release.
Two primary variants are studied in research settings:
- CJC-1295 with DAC — incorporates a Drug Affinity Complex that binds to albumin, extending the half-life to approximately 6–8 days and producing sustained GH elevation
- CJC-1295 No DAC (Modified GRF 1-29) — without the DAC modification, the half-life is approximately 20–30 minutes, producing discrete, pulsatile GH release patterns more closely resembling physiological secretion
What Is Ipamorelin?
Ipamorelin is a selective ghrelin receptor agonist (GHSR-1a) — a pentapeptide that stimulates GH release through an entirely separate pathway from CJC-1295. Rather than activating GHRH receptors, Ipamorelin works through IP3/DAG signaling and calcium mobilization.
Key research characteristics include:
- High selectivity — stimulates GH release with minimal effect on cortisol or prolactin compared to older GHRPs
- Somatostatin suppression — reduces the inhibitory tone on GH release, amplifying overall output
- Short half-life — approximately 2 hours, producing clean, discrete GH pulses
- Well-characterized preclinical safety profile in rodent and primate research models
Why Are They Studied Together?
The combination of Ipamorelin and CJC-1295 is widely referenced in growth hormone research because the two peptides activate different receptor populations simultaneously on the same pituitary somatotroph cells.
- Dual pathway activation — GHRH-R (CJC-1295) and GHSR-1a (Ipamorelin) co-stimulated at the same time
- Amplified GH pulse output — combined pulse amplitude significantly exceeds either compound alone
- Somatostatin reduction — Ipamorelin suppresses the main inhibitor of GH, while CJC-1295 drives release
- Timing dependent — simultaneous administration consistently outperforms sequential dosing in preclinical models
Downstream Research Applications
The GH and IGF-1 signals produced through Ipamorelin and CJC-1295 receptor activation are studied across multiple biological pathways in preclinical research. The following represent areas of active laboratory investigation — not clinical outcomes or therapeutic claims.
- IGF-1 receptor activation and mTORC1 pathway signaling
- Protein synthesis and anabolic signaling models
- Nitrogen retention studies in rodent models
- GH-mediated lipolytic effects on adipocytes
- JAK2/STAT5 signaling pathway research
- Metabolic substrate utilization studies
- Osteoblast GH and IGF-1 receptor interaction
- Bone mineral density models
- Collagen and extracellular matrix signaling
- Nocturnal GH surge amplification studies
- Circadian GH pulse pattern research
- Sleep architecture investigation in rodent models
CJC-1295 with DAC
- Half-life: approximately 6–8 days via albumin binding
- Produces sustained, continuous GH elevation rather than discrete pulses
- Less frequent administration in research protocols
- Better suited for studies requiring stable baseline GH elevation
- Less physiological — sustained levels differ from natural pulsatile patterns
CJC-1295 No DAC
- Half-life: approximately 20–30 minutes
- Produces discrete, pulsatile GH release — closer to natural secretion patterns
- Preferred for combination stack research with Ipamorelin
- Better suited for studying timing-dependent receptor synergy
- More physiological profile in preclinical models
Important Research Notes
- All information on this page is for laboratory and research reference only — not for human or veterinary use
- Ipamorelin and CJC-1295 are supplied in lyophilized form and require reconstitution with bacteriostatic water before laboratory use
- Peptides should be stored properly to maintain integrity — see our How to Store Research Peptides guide
- Each batch is third-party tested with COA documentation available upon request
- Research outcomes described are from preclinical models and do not constitute clinical claims
Frequently Asked Questions
What is the difference between CJC-1295 DAC and No DAC?
CJC-1295 DAC incorporates a Drug Affinity Complex that binds to albumin, extending its half-life to approximately 6–8 days and producing sustained GH elevation. CJC-1295 No DAC has a half-life of approximately 20–30 minutes and produces discrete, pulsatile GH release more similar to natural secretion patterns. The No DAC variant is typically preferred for combination research with Ipamorelin due to its pulsatile profile and timing compatibility.
Why are Ipamorelin and CJC-1295 commonly studied together?
The two peptides operate through completely separate receptor pathways — CJC-1295 activates GHRH receptors while Ipamorelin activates GHSR-1a (ghrelin) receptors. When both receptor types are co-stimulated simultaneously on pituitary somatotroph cells, the resulting GH pulse amplitude is significantly greater than what either compound produces alone. This synergy is why they are frequently referenced together in growth hormone-related preclinical research.
What form does the CJC-1295 + Ipamorelin blend come in?
NexPept supplies a pre-blended vial containing 5mg CJC-1295 No DAC and 5mg Ipamorelin in lyophilized (freeze-dried) powder form. Bacteriostatic water is required for reconstitution prior to laboratory use and is available separately.
Is CJC-1295 + Ipamorelin available for research in Canada?
Yes — NexPept supplies CJC-1295 No DAC + Ipamorelin as a research peptide blend for laboratory use in Canada. All products are third-party tested, batch-tracked, and fulfilled domestically from Ontario with Canada-wide shipping via Xpress Post.
How should this peptide blend be stored in a laboratory setting?
In lyophilized form, the blend should be stored in a cool, dry environment away from light and moisture. Once reconstituted, it should be kept refrigerated and used within a reasonable timeframe to maintain compound integrity. For detailed storage guidance, see our How to Store Research Peptides page.
CJC-1295 No DAC + Ipamorelin Available in Canada
NexPept supplies a pre-blended CJC-1295 No DAC + Ipamorelin research peptide, fulfilled domestically from Ontario with Canada-wide delivery. Every batch is third-party tested and supplied with COA documentation for research traceability.
- 5mg CJC-1295 No DAC + 5mg Ipamorelin per vial — pre-blended for research convenience
- Third-party tested with batch-specific COA documentation available
- Same-day processing on confirmed orders, shipped via Xpress Post
- Canada-wide delivery including PO Boxes and FlexDelivery addresses
Browse Research Peptides in Canada
Lab-tested, batch-tracked research peptides shipped from Ontario. Canada-wide fulfillment via Xpress Post.
All products sold by NexPept are intended for laboratory research use only. They are not intended for human or veterinary use, diagnosis, treatment, or consumption. Information on this page is provided for research reference purposes only and does not constitute medical advice. Preclinical research findings do not guarantee equivalent outcomes in humans.